Lipids News and Research

RSS

Lipids are a broad group of naturally-occurring molecules which includes fats, waxes, sterols, fat-soluble vitamins (such as vitamins A, D, E and K), monoglycerides, diglycerides, phospholipids, and others. The main biological functions of lipids include energy storage, as structural components of cell membranes, and as important signaling molecules.

Study explains why physical activity is beneficial in preventing heart attack and stroke

It is well known that physical activity can improve cardiovascular health. But it's the impact exercise has on specific known risk factors that accounts for about 60 percent of that improvement, researchers reported in Circulation: Journal of the American Heart Association.

22 Oct 2007

First animal model of age-related macular degeneration

Researchers at the University of Pennsylvania School of Medicine have created the first animal model of age-related macular degeneration (AMD) caused by a mutation known to produce disease in people, an important first step in developing treatments.

10 Oct 2007

Linking two molecular pieces may offer new approaches to treating Alzheimer's disease

Researchers have uncovered a biological link between the protein whose mutation causes early-onset Alzheimer's disease (AD) and a gene variant linked to late-onset AD.

4 Oct 2007

Cholesterol levels both high and low linked to premature births

A new study suggests that not only is a very low level of cholesterol a danger to pregnant women, but high cholesterol too increases the risk of premature birth.

3 Oct 2007

Biologists link Huntington's disease to health benefits in young

For years researchers in neurology have believed that people with Huntington's disease have more children than the general population because of behavioral changes associated with the disease that lead to sexual promiscuity.

26 Sep 2007

Scientists decipher mechanism behind antimicrobial 'hole punchers'

In the battle against bacteria, researchers have scored a direct hit.

21 Sep 2007

Process of necrosis redefined in landmark study

A new study led by investigators from the University of Pittsburgh School of Medicine demonstrates that the process of necrosis, long thought to be a chaotic, irreversible pathway to cell death, may actually be triggered as part of a regulated response to stress by a powerful protein, SRP-6, that can potentially halt necrosis in its path.

21 Sep 2007

Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits

Researchers from Boston University School of Medicine (BUSM), Boston University School of Public Health (BUSPH), and the National Heart, Lung and Blood Institute (NHLBI), have completed analyses of a genome-wide scan on a group of two generations of participants from the landmark Framingham Heart Study (FHS).

20 Sep 2007

Pocket guidelines for assessment and management of cardiovascular risk

A new book of pocket-charts that will help health workers to identify people at risk of heart attacks and strokes and save lives by prescribing the most appropriate treatment is published today by the World Health Organization (WHO). The charts can be adapted for use in any setting, in any country, with any patient.

12 Sep 2007

Yellow plant pigments may lower risk for age-related eye disease

Consuming higher levels of the yellow plant pigments lutein and zeaxanthin may be associated with a lower risk for age-related macular degeneration, according to a report in the September issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

11 Sep 2007

A chink in bacteria's armor

Biomedical researchers at Boston University's College of Engineering may have discovered the path toward developing better drugs capable of defeating so-called “superbugs,” bacteria that have developed resistance to common antibiotics. The researchers have discovered a previously unknown chain of events occurring in bacteria that opens to door to new avenues of research.

10 Sep 2007

Abbott and AstraZeneca confirm Phase III clinical trials of Fenofibrate ABT-335 and Crestor as fixed-dose combination

Abbott and AstraZeneca confirmed they will advance the development of Abbott's next-generation fenofibrate ABT-335 and AstraZeneca's CRESTOR (rosuvastatin calcium) in a fixed-dose combination treatment into Phase III clinical trials.

3 Sep 2007

New understanding of endoplasmic reticulum

In obese individuals, fat cells are bloated and inflamed because they receive too many nutrients, including lipids.

29 Aug 2007

Skin-healing pseudoceramides

Researchers report in the September 2007 issue of the Journal of Lipid Research that they have made synthetic lipids called pseudoceramides that are involved in skin cell growth and could be used in treating skin diseases in which skin cells grow abnormally.

29 Aug 2007

Reported failure of vitamin E to prevent heart attacks may be due to underdosing

The findings, published early online in Free Radical Biology and Medicine, suggest that these earlier studies all had a fundamental flaw the doses used werent high enough to have a significant antioxidant effect.

24 Aug 2007

New findings on cholesterol metabolism

A team of researchers investigating cholesterol and lipid transport has performed experiments that cast serious doubt on the dominant hypothesis of how the body rids its cells of "bad" cholesterol (LDL) and increases "good" cholesterol (HDL).

17 Aug 2007

Why is heart disease so prevalent among diabetics?

Heart disease hits people with diabetes twice as often as people without diabetes.

13 Aug 2007

Genomic factors may play a role in alcohol and tobacco use

Alcohol and smoking can be harmful, if not deadly. While the desire for these substances can be due to environmental cues, genomic factors also play an important role.

13 Aug 2007

FGFR4 gene plays a complex role in obesity, fatty liver and diabetes

Researchers at the Texas A&M Health Science Center Institute of Biosciences and Technology at Houston have found that a gene in the liver and elsewhere in the body, when inhibited or increased, affects fatty liver and diabetes but does not alleviate both diseases at once.

11 Aug 2007

Combination of blood pressure-lowering drugs stops loss of kidney function in rare genetic disease

A combination of two types of blood pressure-lowering drugs, an angiotensin-converting enzyme inhibitor (ACEI) plus an angiotensin-receptor blocker (ARB), added to enzyme replacement therapy (ERT) with agalsidase-beta (Fabrazyme, Genzyme Corporation, Cambridge, MA) is the first treatment shown to stop progressive loss of kidney function in patients with severe kidney involvement due to the rare genetic disorder Fabry disease, reports a study in the September Journal of the American Society of Nephrology.

26 Jul 2007